Does Dynavax Need a Do-Over?

I love it when a press release says one thing and the stock price says another -- as if investors are really going to be fooled. Yesterday, Dynavax Technologies (Nasdaq: DVAX  ) used its press-release headline to tout the superior efficacy and safety of its hepatitis B vaccine Heplisav versus GlaxoSmithKline's (NYSE: GSK  ) Engerix-B, but Dynavax's shares fell 19%.

The culprit? While Heplisav continues to invoke a better immune response than Engerix-B with one less shot, the main reason for running the trial was to show that there wasn't an excessive amount of variation between manufacturing lots. In this case, the primary endpoint was consistency in the amount of antibody produced at eight weeks, which Heplisav failed to meet.

But it's a little more complicated than that -- this is biotech, after all. The lot-to-lot variation was consistent enough at 12, 18, 24, and 28 weeks. On the surface, consistency at four time points would seem to balance out an outlier in one time point, but because the primary endpoint failed, the trial wasn't a success.

Management seems to think the FDA might accept the failed experiment as good enough, citing Pfizer's (NYSE: PFE  ) Prevnar 13, which was approved despite missing the prespecified consistency criteria for three of the 13 different strains that the antibody protects against. Of course, three out of 13 is different than one out of one.

Management also implied that the FDA might accept a less stringent definition of consistency than the one Dynavax prespecified. Using the level used by Novartis's (NYSE: NVS  ) Menveo, Heplisav would have passed its consistency endpoint.

Retrospective analysis of data is highly frowned upon by the FDA, because if you look at the data in enough different ways, you're bound to find something that will support your cause.

Dynavax will know soon enough how disapproving the FDA is about its approach. The company has already submitted the data to the agency to see whether it's good enough.

Anything could happen -- as I said, this is biotech -- but investors should plan on seeing a call for another study and then rejoice if it turns out to be unnecessary.

Interested in keeping track of Dynavax as it tries to get Heplisav approved anyway it can? Add it to My Watchlist, which will help you keep track of all our Foolish analysis on Dynavax.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Check out his holdings and a short bio. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline, Novartis, and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 21, 2011, at 5:36 PM, Bumkinpops wrote:

    Saying this trial failed is taking an extremely simplified view of the results. Apparently the fact that the trial demonstrated that Heplisav absolutely crushed the effectiveness of the market leading comparator EngerixB is not worth putting in your article. Or how about the reassuring safety data. Investors were very interested in that as safety concerns have tripped up Heplisav in a previous PIII trial.

    As to the consistency data, the FDA will have the final word, but the failed data point is, in fact, an outlier, so it is very reasonable to look at the entire data set before passing judgement. Looking at the whole picture is a far different thing than data mining. Data mining is picking the outlier data points and using them to bolster your case, and indeed, the FDA justifiably frowns on that as should investors.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1522920, ~/Articles/ArticleHandler.aspx, 11/26/2014 9:21:20 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement